Cyclosporine Ophthalmic

Major

Cyclosporine Ophthalmic Imatinib Gleevec Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Imlunestrant Inluriyo Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Cyclosporine Ophthalmic Indinavir Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Indomethacin Indocin An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Infigratinib Truseltiq Increased infigratinib plasma concentrations Details Cyclosporine Ophthalmic Infliximab Avsola Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Influenza Virus Vaccine, Live An inadequate immunological response to the vaccine, increased risk of disseminated infection with live vaccines and reduced effic... Details Cyclosporine Ophthalmic Irbesartan Avapro An increased risk of hyperkalemia Details Cyclosporine Ophthalmic Isavuconazole Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Isavuconazonium Cresemba Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Istradefylline Nourianz Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Itraconazole Sporanox Increased cycloSPORINE exposure and risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Ivacaftor Kalydeco Increased ivacaftor exposure and/or increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Ivosidenib Tibsovo Increased ivosidenib exposure and an increased risk of QT interval prolongation Details Cyclosporine Ophthalmic Ketoconazole Extina An increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Ketoprofen Actron® An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Ketorolac Acular An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Lanreotide Decrease the relative bioavailability of cycloSPORINE Details Cyclosporine Ophthalmic Lapatinib Tykerb Increased cycloSPORINE exposure Details Cyclosporine Ophthalmic Larotrectinib Increased larotrectinib exposure and increase in the incidence or severity of adverse reactions Details Cyclosporine Ophthalmic Lasmiditan Reyvow Increased exposure of P-gp substrate and risk of toxicity Details Cyclosporine Ophthalmic Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Cyclosporine Ophthalmic Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, increased cycloSPORINE exposure and an inc... Details Cyclosporine Ophthalmic Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Cyclosporine Ophthalmic Lenacapavir Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Cyclosporine Ophthalmic Lesinurad Reduced cycloSPORINE exposure Details Cyclosporine Ophthalmic Letermovir Prevymis Increased cycloSPORINE exposure and an increased letermovir exposure Details Cyclosporine Ophthalmic Levamlodipine Conjupri Increased cyclosporine concentrations Details Cyclosporine Ophthalmic Levonorgestrel After banger Increased cycloSPORINE exposure and an increased risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Cyclosporine Ophthalmic Lisinopril Prinivil Acute renal dysfunction and an increased risk of hyperkalemia Details Cyclosporine Ophthalmic Lomitapide Increased lomitapide exposure and an increased P-gp substrate exposure Details Cyclosporine Ophthalmic Lonafarnib Zokinvy Increased cycloSPORINE exposure and an increased risk of cycloSPORINE-related adverse effects and serious or life-threatening toxi... Details Cyclosporine Ophthalmic Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Cyclosporine Ophthalmic Lorlatinib Lorbrena Reduced P-gp and CYP3A4 substrates exposure and reduced efficacy of P-gp and CYP3A4 substrates Details Cyclosporine Ophthalmic Lornoxicam An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Losartan Arbli An increased risk of hyperkalemia Details Cyclosporine Ophthalmic Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Cyclosporine Ophthalmic Loxoprofen An increased risk of cycloSPORINE nephrotoxicity Details Cyclosporine Ophthalmic Lumacaftor Reduced exposure to immunosuppressant Details Cyclosporine Ophthalmic Lumiracoxib An increased risk of cycloSPORINE nephrotoxicity Details